Teva Pharmaceutical Industries (NYSE:TEVA) Stock Breaks Below 50 Day Moving Average - Here's Why

Teva Pharmaceutical Industries logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Teva shares fell below their 50-day moving average: The stock traded as low as $38.51 and last stood at $38.53, versus a 50-day average of $40.56.
  • Analyst sentiment remains broadly positive despite the share-price weakness: 14 analysts rate the stock Buy, and the average price target is $48.64.
  • Chief Medical Officer Eric Hughes is leaving, creating a leadership transition in R&D; Teva says its strategy and goal of $6–7 billion in innovative-medicines revenue by 2030 remain unchanged. The company also beat quarterly earnings and revenue estimates, although revenue declined 1.9% year over year.
  • Interested in Teva Pharmaceutical Industries? Here are five stocks we like better.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report)'s share price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $40.56 and traded as low as $38.51. Teva Pharmaceutical Industries shares last traded at $38.53, with a volume of 10,369,385 shares changing hands.

Key Headlines Impacting Teva Pharmaceutical Industries

These are some of the TEVA headlines that stood out recently:

  • Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an Overweight rating. Argus also raised its target to $50 and reaffirmed a Buy rating, while HC Wainwright maintained its Buy rating. Barclays analyst action Argus forecast HC Wainwright rating
  • Neutral Sentiment: Teva said its R&D strategy, priorities and commitments remain unchanged, including its goal of $6–7 billion in innovative-medicines revenue by 2030. David Gardiner will lead the transition while the company searches for a permanent successor. Teva leadership announcement
  • Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an opportunity outside Teva. His departure may unsettle investors given the importance of R&D execution to the company’s growth strategy, despite his planned support during the transition. R&D leadership transition report

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. UBS Group raised their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a "buy" rating in a research report on Friday, September 4th. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. HC Wainwright reissued a "buy" rating and issued a $54.00 price target on shares of Teva Pharmaceutical Industries in a research report on Tuesday. Leerink Partners boosted their price objective on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th. Finally, Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an "overweight" rating in a research report on Thursday, November 12th. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $48.64.

Check Out Our Latest Analysis on TEVA

Teva Pharmaceutical Industries Price Performance

The stock has a market cap of $44.90 billion, a PE ratio of 89.61, a P/E/G ratio of 3.66 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The firm's 50 day moving average price is $40.56 and its two-hundred day moving average price is $35.22.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The company had revenue of $4.39 billion for the quarter, compared to analysts' expectations of $4.23 billion. During the same period in the prior year, the company posted $0.78 EPS. Teva Pharmaceutical Industries's revenue was down 1.9% compared to the same quarter last year. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, CEO Richard Francis sold 250,000 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the sale, the chief executive officer owned 927,529 shares of the company's stock, valued at approximately $39,178,824.96. This represents a 21.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian Savage sold 7,342 shares of the firm's stock in a transaction that occurred on Friday, September 18th. The shares were sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the transaction, the insider owned 8,500 shares of the company's stock, valued at $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 715,945 shares of company stock worth $29,061,351 in the last 90 days. 0.54% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 1.3% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company's stock worth $1,561,120,000 after buying an additional 500,000 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 20.0% in the third quarter. Goldman Sachs Group Inc. now owns 7,355,669 shares of the company's stock worth $291,284,000 after purchasing an additional 1,226,429 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Teva Pharmaceutical Industries by 5.8% in the second quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company's stock valued at $259,899,000 after acquiring an additional 419,329 shares during the period. Janus Henderson Group PLC increased its holdings in Teva Pharmaceutical Industries by 1.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company's stock valued at $145,076,000 after purchasing an additional 72,880 shares during the period. Finally, Marshall Wace LLP bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $110,197,000. 54.05% of the stock is currently owned by institutional investors.

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?

Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines